The performance of methods used for the measurement of urinary-free cortisol (UFC) has been monitored in the UK by an external quality assessment scheme (EQAS). Bias and variation of the bias (VAR) from the all laboratories trimmed mean
(AL TM) show that mean bias ranged from -15·5070 to + 83 . 1% and mean VAR from 9·3 % to 53·2 %. The dominant kit methods had a bias range of -4·2% and + 56· 9% and VAR between 11·4% and 18· 4%. Recovery of added cortisol ranged from 74·9% to 207·2%. The precision of the estimate of urinary-free cortisol was different for different methods and changed with concentration.
When methods were compared with a gas chromatography mass spectroscopy (GCMS) target there was a linear correlation between per cent bias from the AL TM and from the GCMS result with the AL TM averaging 63·1 % greater than the GCMS value.
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The biochemical detection or differential diagnosis of hypercortisolism is clinically important in order that suitable treatment may be given as early as possible. One of the most valuable and simplest screening tests is the measurement of UFC which has been shown to have a sensitivity of 94·4% and a specificity of 96·7% in the diagnosis of hypercortisolism.' Collection of urine samples during dexamethasone suppression tests can also be of value to supplement serum cortisol or plasma ACTH estimations.
UFC is cortisol in urine that is not conjugated to amino acids or glucuronic acid. It is derived from the portion of the non-protein bound cortisol that circulates in blood. Cortisol in blood circulates mainly bound to cortisol binding globulin (CBG). Under normal circumstances only about 5% of cortisol is 'free' or non-CBG bound. The CBG becomes fully saturated at around 550 nmollL, so in hypercortisolaemia the binding capacity of the CBG is exceeded and the free fraction rises rapidly and disproportionately to the total circulating levels. This in turn leads to greater filtration of the free cortisol at the 84 glomerulus and thus an increase in UFC. About 95% of filtered cortisol in reabsorbed. Small changes in the reabsorbed fraction can cause large changes in urinary excretion, but fortunately this is not often associated with hypercortisolism although it should be born in mind when considering interpretation.
One major problem of UFC measurements is that of incomplete urine collections. Attempts have been made to correct for this by using timed collections for 4 h 2 or early morning samples with the measurement of UFC/creatinine ratio.! These tests yield information equivalent to accurate 24 h UFC measurements.
Early measurement was by a colorimetric or fluorimetric technique after initial solvent extraction to concentrate the cortisol and reduce the effects of conjugates and non-specific interferences." Later CBG itself was employed in competitive protein binding assays (CPB) using radioisotopes and various separation procedures. 5 Radioimmunoassay (RIA) is now the method of choice for most routine applicationss-? but methods such as HPLC are also used."
The performance of methods measuring UFC has been assessed by the United Kingdom National Quality Assessment Scheme (UKNEQAS) since 1985. This paper reviews the current status of the methods and compares them with a specific GCMS target.
MATERIALS AND METHODS
Data from the UKNEQAS were collected over a period of 12 months from April 1992-March 1993. At that time there were 101 laboratories in the scheme using 15 different kit methods plus a variety of in-house techniques. There was one distribution of four aliquots of urine each month.
Urines were single collections from normal subjects or patients known to have hypercortisolism. Certain donors with hypercortisolism were treated with metyrapone and one with cytotoxic agents. Some collections may have been then pooled. The donors were prospectively tested for hepatitis antigen and HIV. The urines were collected without preservatives and stored frozen for pre-distribution processing. Processing consisted of filtration through a O:21L GVLP filter using a Minitan system (Millipore Ltd, London, UK). The filtered urine was treated with sodium azide (0' 10/0) and frozen and stored in aliquots at -20°C prior to distribution, by first class post. Results were returned within 4 weeks of receipt and data analysis was carried out using the unified NEQAS software developed by the Wolfson Laboratories (Birmingham, UK).
The study investigated by method the recovery, reference ranges, bias from a target value, precision of the bias and interference from certain urines. Method accuracy was assessed against a GCMS reference method and the bias from the routine target value of the scheme.
Recovery experiments were done by adding cortisol dissolved in ethanol to a basal urine pool ensuring that the maximum ethanol concentration was less than O' 1%. The recovery pools were equilibrated overnight at 4°C after addition of cortisol before aliquots were prepared and distributed as routine NEQAS pools.
Assessment of performance was against the ALTM. The ALTM includes methods using solvent extraction as well as direct assays. Limits for the 6 month cumulative bias from the AL TM (CBIAS) and VAR are set by the National Quality Assurance Panel for Chemical Pathology. The current limit for bias is 25% and VAR 20%.
GCMS targets
Five of the routine pools were chosen for a preliminary investigation of the performance of UFC methods using a GCMS target value. These pools were all from two patients, one male (three samples) the other female (two samples), with proven Cushing's syndrome. Neither patient was on treatment at the time of urine collection. The urine had been stored frozen at -20°C after filtration and treatment with sodium azide.
GCMS method for UFC
This was a modification of the GCMS method for serum cortisol. 9 Cortisol was extracted from the urine (100 ILL) with dichloromethane (3 mL) after equilibration with internal standard [9,1l,12,12-2H 4 J cortisol (KOR Isotopes, Cambridge, MA, USA) in water, 400 ILL. The aqueous phase was removed and the solvent washed with water. It was transferred to a silanized tube and the dichloromethane evaporated under nitrogen at 40°C.
A two-stage derivative procedure was carried out first with methoxylamine hydrochloride in pyridine for 16 h at 20°C. After evaporation, 15 ILL of the reagent, N-methyl-N-trimethylsilyltrifluoroacetamide, trimethylbromosilane, cyclohexane (150: 5: 850 v/v) was added and the reaction allowed to proceed for 30 min at 60°C. This reagent was evaporated and the residue taken up in hexane for GCMS. Reagents were obtained from Fisons Scientific, Loughborough, UK. Analar solvents were all fractionally redistilled on 150 em columns using Fensk helices.
Gas chromatography was carried out on a Dani 3800 gas chromatograph using a 10 m DBI fused silica capillary column 0·25 mm diameter, phase thickness 0·25 ILm (J & W Scientific, Jones Chromatography, Hengoed, Wales, UK). Column temperature was 260°C with a helium pressure of O' 5 bar. The injection mode was an all glass needle prepared in-house. Injection temperature was 260°C and detection temperature 265°C. The column exit led directly into the mass spectrometer ion source. Selected ion recording was performed on a VG 7070 HS mass spectrometer at a resolution of 700. Cortisol bis methyloxime tris trimethylsilylether and its derivatized analogue were monitored at the mass of their M-31 ions, 605 and 608, respectively. The peak height ratios for the analyte/internal standard were assessed and UFC concentrations calculated from a standard curve established for each assay. The final values were calculated in nmol/L.
GeMS assay validation
Validation data for serum are as follows; the method for urine was identical except for substitution of the specimen. Recovery of added cortisol was assessed by adding 275, 1103 and 2207 nmol/L to serum and analysing the samples. Three samples were analysed five times each in one batch to measure within batch precision. Parallelism was assessed using 50, 125, 250 and 400 J.lL of sample. The amount of cortisol derivative injected to give a signal/noise ratio of 10: 1 was used to give an indication of sensitivity
RESULTS
The UKNEQAS is dominated by two groups of kit users. The Coat-A-Count kit (Diagnostic Products (UK) Ltd, Abingdon, UK) is used by 3511,10 of participants and Orion Diagnostica-Farmos in this paper-(Pharmacia Ltd, Milton Keynes, UK) a further 26%. There were 15% of labs using non-isotopic endpoints on some form of automated system.
Urine pools are chosen for distribution to monitor the likely diagnostic range. The upper limit of the adult reference range for UFC is from 250-350 nmol/24 h depending on the kit used. The AL TM for the pools distributed over the 12 months to May 1993 ranged from 90·6-1543 nmol/24 h; 54% of pools had concentrations greater than 250 nmol/L. Recovery of added cortisol is shown in Table 1 . It was calculated by regression analysis using the amount of added cortisol as the abscissa and the trimmed method mean as the ordinate. The slope of the linear regression line is therefore the overall fractional recovery and the intercept the UFC concentration of the base pool. The methods have been ranked by overall recovery. Also shown in Table I are the mean reference ranges taken from a survey of participants. There can be significant differences in values quoted by participants using the same kit. In some cases manufacturers' ranges printed in kit inserts show large discrepancies compared to those accepted by laboratories. Values for overall recovery varied from 74·9% (Farmos) to 207· 2% (Abbott TDX direct). The AL TM recovery was linear. The estimate of UFC in the base pool varied widely and was not proportional to the recovery. It should be noted that the Farmos method changed antiserum near the start of the study and this improved the recovery to 92· 3% in a more recent experiment.
Results were calculated as bias from the ALTM and the CV (or variation) of the bias (VAR). Limits for acceptable bias and VAR have A"" eli" Biochem 1995: 32
., Table 1for key to manufacturers. Table 2 ). The majority of labs that failed to meet the criterion bias used non-extraction protocols (Abbott TDX direct, Amerlex, DPC direct). Figure I shows the median bias, the interquartile range (IQ) and the extremes of bias for the various method groups. Figure 2 shows similar plots for VAR. It can be seen that there was a wide range of bias that was not proportional to recovery of added cortisol nor was it related to whether the sample was extracted. Mean bias ranged from -15· 5070 (Farmos) to 83 ·1070 (IDS direct). The dominant kit methods had a bias range between -4· 2070 (DPC extraction) and 56· 9070 (Amerlex). Mean VAR ranged from 9·3070 (DPC DAb) to 53·2070 (IDS direct). The most frequently used kit methods had a VAR between 11·4070 (Farmos) and 18·4070 (Amerlex).
Median, interquartile and extreme range of bias from the all laboratories trimmed mean (a). Only mean values are shown for minor methods (b). Ext = extraction. See
The precision of the estimate of UFC was different for different methods and changed with concentration. Figure 3 shows the CV for the main methods compared to concentration of the AL TM. The two direct methods, Farmos and Amerlex tended to have a lower CV across the range than the extraction methods. The heterogeneity of the home RIA group was shown by a very high CV at all concentrations.
Validation studies of the GCMS technique showed that recovery of added cortisol was virtually quantitative. The mean value was 99·0070 (CV 3· 9070). Within batch precision was 1· 42070, 0·8070 and 1·27070 (CV) at 52, 412 and 1020 nmollL, respectively. The assay showed parallelism on dilution; 50, 125,250 and 400 JLL gave 710,681,679 and 687 nmollL, respectively. At a signal to noise ratio of 10: I the concentration of cortisol was equivalent to 0·7 nmollL. Figure 4 shows the median bias from the GCMS target value for the five pools for each method together with the extreme range for that bias. Figure 5 shows CBIAS for each method plotted against the bias from the GCMS target for the five pools. CBIAS includes all pools, not just those measured by GCMS. There was a linear correlation between CBIAS and GCMS bias with an ALTM bias of + 63· 1070. ALTM bias ranged from -25· 7070 (CPB) to + 104070 (Kodak Amerlite). Elias lrom GCMSia,get ("!o) FIGURE 4. Median bias and extreme range of bias from the gas chromatography mass spectroscopy (GCMS) value for the different method groups. See Table I for key to manufacturers.
....
.... ..... Table I for key to manufacturers. Figure 6 shows the difference in bias of untreated, cytotoxic drug treated and metyrapone treated patients for a direct kit. There is a significant change in bias from the AL TM for the pools from treated patients, particularly for the sample after cytotoxic chemotherapy. Figure 7 shows performance when the pools from treated patients were distributed. Nearly 601I7o of labs had unacceptable performance. As these pools were replaced by samples from untreated Cushing's patients, the effect disappeared. ... 
FIGURE 2. Median, interquartile and extreme range of variationofthe bios (a). Only mean valuesareshown for minor methods (b). See

DISCUSSION
RIA has been used for serum cortisol and UFC measurement for many years. The high concentration of cortisol in serum and urine compared to other steroids such as oestradiol has made accurate and precise measurement much easier. This has led to very satisfactory performance for serum cortisol assays which is reflected in the UKNEQAS performance. Unfortunately, the same situation is not true for the measurement of UFC and its performance in the UKNEQAS.
One of the problems of measuring UFC is the large number of potentially interfering substances in urine. Many of these are steroids or steroid conjugates that may be present in very high concentration. These can prove to be a particular problem in direct assays as solvent extracts leave behind the more polar conjugates. Very few of these substances have been tested for their crossreaction by commercial manufacturers. Those tested are usually the unconjugated steroid, even in kits with non-solvent extraction protocols.
The extent of these effects was revealed by experiments in 1991 when samples from patients treated with metyrapone and after cytotoxic chemotherapy were distributed. These patients had hypercortisolism caused by pathology of the hypothalamic-pituitary-adrenal axis. Metyrapone is an 11~-hydroxylase inhibitor that causes a significant risein 11-deoxycortisol and consequently its urinary metabolites. Some cytotoxic chemotherapy may be hepatotoxic leading to fibrosis, cirrhosis or necrosis of the liver. This may interfere with the liver breakdown of steroids. Kits using direct assay performed noticeably worse with these pools compared to urine collections from controls and untreated patients with Cushing's syndrome. The change was shown by an anomalous bias leading to large increases in VAR. All Amerlex users had unacceptable performance with these pools. Farmos users showed deterioration of the VAR whilst the DPC Extraction kit was not so severely affected. The bias for a few pools is much greater than the rest but it is not always the same pool or pools for different methods. One possible conclusion from this is that if true clinical samples are distributed by the NEQAS then the data should be included in the cumulative analysis only if they do not affect the perceived performance of chosen methods and the pools should be chosen to fit the method. The alternative view is that one of the roles of UKNEQAS is to expose any weakness or anomaly in method performance and all results are relevant.
CONCLUSIONS
As with all analytical procedures there are many factors that affect the reliability of the final UFC measurement. In all cases, commercial kits and methods appear to treat UFC as an add-on method to a kit designed for serum cortisol. Although data may be presented for urine they are rarely as extensive as that for serum. Indeed some manufacturers offer protocols for solvent extraction and direct measurement that yield vastly differing results. If UFC can be regarded as a specific analyte, only one could therefore be correct. The current UKNEQAS results for UFC indicate that specificity is a major problem. It is likely that only a percentage of the measured value is true UFC. This is clearly shown by the GCMS target pools where all methods have a positive bias. The fact that there is a linear relationship of the GCMS bias to the AL TM bias gives some confidence that the use of the AL TM as a target has analytical validity. Extreme bias of a method from the AL TM target would indicate poor specificity or inappropriate standardization for UFC. Lack of specificity may not matter in diagnosis. In patients with hypercortisolaemia the contribution of other metabolites to UFC may increase the sensitivity of the test compared to highly specific cortisol estimations, but this remains to be proven.
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Analytically, the current goal should be as accurate and precise measurement as possible.
